Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. / Petersen, T R; Bregenholta, S; Pedersen, L O; Nissen, Mogens Holst; Claesson, M H.

In: Cancer Letters, Vol. 137, No. 2, 1999, p. 183-91.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Petersen, TR, Bregenholta, S, Pedersen, LO, Nissen, MH & Claesson, MH 1999, 'Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.', Cancer Letters, vol. 137, no. 2, pp. 183-91.

APA

Petersen, T. R., Bregenholta, S., Pedersen, L. O., Nissen, M. H., & Claesson, M. H. (1999). Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Letters, 137(2), 183-91.

Vancouver

Petersen TR, Bregenholta S, Pedersen LO, Nissen MH, Claesson MH. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Letters. 1999;137(2):183-91.

Author

Petersen, T R ; Bregenholta, S ; Pedersen, L O ; Nissen, Mogens Holst ; Claesson, M H. / Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. In: Cancer Letters. 1999 ; Vol. 137, No. 2. pp. 183-91.

Bibtex

@article{e0e43940ba3111ddae57000ea68e967b,
title = "Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.",
abstract = "C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.",
author = "Petersen, {T R} and S Bregenholta and Pedersen, {L O} and Nissen, {Mogens Holst} and Claesson, {M H}",
note = "Keywords: Animals; COS Cells; Cytotoxicity Tests, Immunologic; Dendritic Cells; Gene Expression; HLA-A2 Antigen; Humans; Immunity, Cellular; Immunodominant Epitopes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments; T-Lymphocytes, Cytotoxic; Transfection; Tumor Suppressor Protein p53; Vaccines, DNA",
year = "1999",
language = "English",
volume = "137",
pages = "183--91",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.

AU - Petersen, T R

AU - Bregenholta, S

AU - Pedersen, L O

AU - Nissen, Mogens Holst

AU - Claesson, M H

N1 - Keywords: Animals; COS Cells; Cytotoxicity Tests, Immunologic; Dendritic Cells; Gene Expression; HLA-A2 Antigen; Humans; Immunity, Cellular; Immunodominant Epitopes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments; T-Lymphocytes, Cytotoxic; Transfection; Tumor Suppressor Protein p53; Vaccines, DNA

PY - 1999

Y1 - 1999

N2 - C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.

AB - C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.

M3 - Journal article

C2 - 10374840

VL - 137

SP - 183

EP - 191

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -

ID: 8746407